(NASDAQ: CGON) Cg Oncology's forecast annual revenue growth rate of 341.93% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Cg Oncology's revenue in 2026 is $5,071,000.On average, 16 Wall Street analysts forecast CGON's revenue for 2026 to be $382,798,733, with the lowest CGON revenue forecast at $86,438,424, and the highest CGON revenue forecast at $1,690,223,990. On average, 16 Wall Street analysts forecast CGON's revenue for 2027 to be $8,713,522,308, with the lowest CGON revenue forecast at $3,457,536,942, and the highest CGON revenue forecast at $14,751,863,609.
In 2028, CGON is forecast to generate $43,533,212,574 in revenue, with the lowest revenue forecast at $18,420,204,461 and the highest revenue forecast at $66,958,907,378.